Enzon Pharmaceuticals About
Enzon Enzon Pharmaceuticals is a biopharmaceutical company
dedicated to the discovery, development and commercialization of therapeutics
to treat life-threatening diseases. The Company has developed or acquired a number
of marketed products, including PEG-INTRON®, marketed by Schering-Plough, and
ABELCET®, ONCASPAR®, ADAGEN®, and DEPOCYT®, marketed in North America by Enzon’s
specialized sales force. Drugs
Under Development for Enzon ATG-Fresenius S,
a polyclonal antibody preparation used for T-lymphocyte suppression in organ transplant
patients MARQIBO® (vincristine sulfate liposomes injection) as a
treatment for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL).
SS1P is a fusion protein, or immunotoxin, consisting of a disulfide
linked antibody fragment linked to domains II and III of Pseudomonas exotoxin
A. More
on Ezon